Financial Highlights

Revenue

(£m)

Underlying EBIT1

(£m)

Adjusted Basic EPS1

(pence)

Dividend Per Share

(pence)

  1. Underlying figures are as defined in the Alternative Performance Measures section in the Notes to the Consolidated Accounts and are stated before special items of £20.9m that include amortisation of acquired intangibles, reorganisation and impairment costs (FY2017: £13.7m).

Operational Highlights

  • Continued growth across our broad range of leading drug delivery devices
  • Ongoing support to Mylan on the potential launch of their generic Advair programme
  • Good progress in developing our Syrina®/Vapoursoft® auto-injectors for our leading global biopharmaceutical customer and further interest from other significant potential customers
  • Agreement with our major biopharmaceutical customer to commence industrialisation activities for facilities, production processes and tooling for a potential product launch of the Syrina®/ Vapoursoft® auto-injector
  • Record volumes were manufactured at our German and Italian facilities with investments being made in new production lines to support growth
  • Formal award of a significant multi-year active pharmaceutical ingredient (API) supply contract for an innovative new product at our Cramlington facility
  • Awards of finished dose and packaging contracts and renewal of long-term contracts with existing customers
  • New customers on the semi-continuous processing line and technology installed in our Queenborough site